Drugs brought to registration

According to an analysis by Pecoul et al(1), of the 1233 new drugs identified as reaching the market between 1975 and 1997, only 13 were approved for tropical diseases. Of these 13, six were developed with TDR support. Since then, additional chemical entities or drug combinations have been registered for the treatment of tropical diseases with input from TDR.

Drug Year of registration Indication Partners
Praziquantel 1980 Schistosomiasis Bayer
Mefloquine 1984 Malaria Hoffman La Roche, WRAIR
Ivermectin 1987 Onchocercosiasis Merck
Halofantrine 1988 Malaria Smith Kline Beecham, WRAIR
Eflornithine 1991 African trypanosomiasis Marion Merrel Dow
Liposomal amphotericin B 1994 Leishmaniasis (Kala azar) NeXstar
Artemether 1997 Malaria Rhone Poulenc Rorer, Kunming
Artemether-umefantrine 1999 Malaria Novartis
Artemotil (beta-arteether) 2000 Malaria Artecef, WRAIR, Dutch Min. Dev.
Miltefosine 2002 Leishmaniasis (Kala azar) Zentaris, Indian CMR
Chlorproguanil-dapsone 2003 Malaria Glaxo Smith Kline, DFID

(1) Pecoul, B. et al. (1999) Access to essential drugs in poor countries: A lost battle? Journal of the American Medical Association, 281(4): 361-367


TDR's ability to build partnerships between public and private sectors, industry, academia, and developed and developing countries, reduced the costs and risks involved in bringing new drugs for tropical diseases to registration. TDR:

  • Brought partners together and provided strategic funding and technical support
  • Mobilized a global network of researchers and developers capable of addressing all aspects of research and development from discovery through to registration
  • Funded preclinical studies and research into discovery of new therapeutic targets
  • With industry partners, orchestrated, sponsored and coordinated clinical trials in disease endemic countries following strict standards and regulatory requirements.